Critical appraisal of bevacizumab in the treatment of ovarian cancer

Bevacizumab is the first molecular-targeted agent to be used for the treatment of ovarian cancer. Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor. Two randomized Phase III trials evaluated the combination of bevacizumab plus standard cytotoxic chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshida, Hiroyuki, Yabuno, Akira, Fujiwara, Keiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423500/
https://www.ncbi.nlm.nih.gov/pubmed/25960638
http://dx.doi.org/10.2147/DDDT.S83275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423500/
https://www.ncbi.nlm.nih.gov/pubmed/25960638
http://dx.doi.org/10.2147/DDDT.S83275

Ejemplares similares